Fibrocell Science (NASDAQ: FCSC) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk.
This is a breakdown of recent recommendations and price targets for Fibrocell Science and ANI Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Fibrocell Science presently has a consensus price target of $5.53, indicating a potential upside of 237.40%. ANI Pharmaceuticals has a consensus price target of $67.33, indicating a potential upside of 8.90%. Given Fibrocell Science’s stronger consensus rating and higher probable upside, equities analysts clearly believe Fibrocell Science is more favorable than ANI Pharmaceuticals.
Risk & Volatility
Fibrocell Science has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 2.85, suggesting that its stock price is 185% more volatile than the S&P 500.
Valuation and Earnings
This table compares Fibrocell Science and ANI Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Fibrocell Science||$350,000.00||68.97||-$15.29 million||($1.96)||-0.84|
|ANI Pharmaceuticals||$128.62 million||5.60||$3.93 million||$0.64||96.61|
ANI Pharmaceuticals has higher revenue and earnings than Fibrocell Science. Fibrocell Science is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares Fibrocell Science and ANI Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
54.7% of Fibrocell Science shares are held by institutional investors. Comparatively, 56.5% of ANI Pharmaceuticals shares are held by institutional investors. 2.1% of Fibrocell Science shares are held by company insiders. Comparatively, 31.8% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
ANI Pharmaceuticals beats Fibrocell Science on 9 of the 13 factors compared between the two stocks.
Fibrocell Science Company Profile
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.